Successful Portfolios LLC Invests $221,000 in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Successful Portfolios LLC bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,362 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Private Ocean LLC bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $28,000. Lenox Wealth Advisors LLC increased its stake in Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares during the period. Endurance Wealth Management Inc. increased its stake in Bristol-Myers Squibb by 119.6% in the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 500 shares during the period. HMS Capital Management LLC purchased a new position in Bristol-Myers Squibb in the 2nd quarter worth about $45,000. Finally, Global Trust Asset Management LLC increased its stake in Bristol-Myers Squibb by 251.1% in the 2nd quarter. Global Trust Asset Management LLC now owns 3,511 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 2,511 shares during the period. Hedge funds and other institutional investors own 80.17% of the company’s stock.

NYSE BMY traded up $0.83 during trading on Friday, reaching $51.61. 11,252,303 shares of the company’s stock traded hands, compared to its average volume of 9,791,409. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The firm has a market cap of $82.38 billion, a price-to-earnings ratio of 12.97, a price-to-earnings-growth ratio of 2.48 and a beta of 0.72. The company’s 50 day simple moving average is $49.24 and its two-hundred day simple moving average is $47.03. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $60.77.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. The business had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.01 EPS. Research analysts expect that Bristol-Myers Squibb Co will post 4.29 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

BMY has been the topic of several recent analyst reports. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target on the stock in a research note on Wednesday, August 14th. Bank of America raised their price target on shares of Bristol-Myers Squibb from $49.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research note on Thursday, June 13th. TheStreet raised shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research note on Wednesday, September 18th. Finally, JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Buy” and an average price target of $55.81.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini bought 11,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were acquired at an average price of $44.72 per share, with a total value of $491,920.00. Following the transaction, the director now owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: P/E Growth (PEG)

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.